{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-003380","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.266419+00:00","generated_at":"2026-06-07T00:31:48.544134+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunome plans three INDs by 1Q 2025; closes Zentalis ADC license, Atreca antibody purchase","bullets":["Zentalis ADC license: $35M upfront (cash+stock), $275M milestones, mid-to-high single digit royalties for ROR1 ADC IM-1021.","Atreca antibody purchase: $5.5M cash upfront, $7M milestones for over 25 preclinical antibodies; closing subject to shareholder approval.","IND filings planned for 1Q 2025 for FAP radioligand therapy, ROR1 ADC (IM-1021), and IL-38 immunotherapy.","AbbVie collaboration: $30M upfront, up to $70M platform payments, $120M per target milestones, $150M per target sales milestones.","Preclinical data shows IM-1021 superior to MK-2140 in TNBC model; proprietary payload outperforms Enhertu in HER2-low model."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-003380","json":"https://secwatch.observer/filing/0001104659-24-003380.json","markdown":"https://secwatch.observer/filing/0001104659-24-003380.md","text":"https://secwatch.observer/filing/0001104659-24-003380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924003380/0001104659-24-003380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924003380/tm242340d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:31:48.544134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}